NSCs exert direct anti-tumor effects by modulating pathways such as p53, protein kinase B (AKT), extracellular signal-regulated kinases 1 and 2 (ERK) 1/2, and the mammalian target of rapamycin (mTOR), leading to apoptosis via caspase-3. Here, AKT1 is linked to neoplasm.